Entecavell ODT

Phase 2Small molecule

UUnknown Sponsor

Entecavell ODT is one of 2 small molecule programs targeting Hepatitis B Virus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatitis B VirusNot yet recruiting

Hepatitis B VirusPhase 2

Not yet recruiting

Competition

Competitive Landscape

1 competitor in Hepatitis B Virus

#DrugCompanyPhaseTrials

Entecavell ODT

UUnknown Sponsor

Phase 2

1 2

Hepb Mab19

RRockefeller University

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Not yet recruiting

Hepatitis B Virus

NCT07267208

Clinical

Trials by Indication[1]

Hepatitis B Virus1 trial

A Prospective Study to Evaluate the Efficacy and Safety of Entecavir ODT Conversion in Stable Liver Transplant Patients

Not yet recruiting·UUnknown Sponsor·Phase 2·NCT07267208·82 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Entecavell ODT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Entecavell ODT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Entecavell ODT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Unknown Sponsor company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUnknown Sponsor

Entecavell ODT

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Hepatitis B Virus1 trial

References

Drug Info

Quick Facts

Related News